2125.HK

TV drama producer and distributor Strawbear Entertainment Group (2125.HK) said on Tuesday it expects to report it swung into the red in the first half of 2025, citing a smaller volume of its dramas that were aired during the period.

The company said it expects to report a net loss of between 3.5 million yuan ($488,000) and 8 million yuan for the six months through June, reversing a profit of 29.9 million yuan in the year-ago period. It added that on an adjusted basis, it expects to report between a net loss of about 2.9 million yuan and a profit of 1.6 million yuan for the first half of 2025, compared with a net profit of 37.9 million yuan a year earlier.

“The above changes were primarily attributable to a decrease in revenue, resulting from the reduced number of episodes broadcast as the episode contents broadcast by the group in the first half of 2025 were ‘boutique and premium’ innovative episodic contents with smaller number of episodes, while the group’s operating cost remained relatively stable,” it said.

Strawbear’s stock opened lower on Wednesday and was down 6.7% at HK$0.56 in early trade. The stock is up about 18% this year.

By Doug Young

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?
So-Young runs cosmetic surgery clinics

Can So-Young find new youth in bricks and mortar?

The cosmetic surgery specialist’s top line is growing as it opens new ‘light medical aesthetic’ clinics, but its bottom line is sagging as its older platform business evaporates Key Takeaways:…
CSPC delivered lower nine-month revenues and profits

CSPC feels the pain from sweeping cuts in drug prices

The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…